Europe Pharmaceutical Drug Delivery Market Size, Share & Growth
The Europe pharmaceutical drug delivery market is expected to grow from USD 519.62 billion in 2026 to USD 703.19 billion by 2031, with a CAGR of 6.2%.
Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=148622116
The market growth is driven by rising use of biologics and biosimilars, an increasing prevalence of chronic diseases, and growing acceptance of innovative drug delivery devices, including auto-injectors, prefilled syringes, and inhalation systems. An aging population, rapid adoption of home care, and supportive regulatory policies promoting patient-friendly drug delivery systems are also fueling this growth.
- Germany is expected to grow at a CAGR of 7.2% during the forecast period.
- The injectable drug delivery segment held the largest market share of 38.0% in 2025.
- The autoimmune diseases segment is expected to record the highest CAGR of 7.6% from 2026 to 2031.
- The hospitals segment held the largest market share of 58.8% in 2025.
- Gerresheimer AG (Germany) and Novo Nordisk (Denmark) stand out as star players in Europe because of their strong regional footprint, established product portfolios, and consistent leadership in advancing drug delivery technologies.
- Capa Valve Ltd (Belgium) and Pharma Latch (UK) are emerging players, gaining attention for their novel approaches to improving precision, ease of use, and patient experience in drug delivery.
In Europe, there is a rising interest in innovative drug delivery systems as healthcare systems seek ways to improve drug administration. Germany, France, and the Nordic countries are leading this effort with their healthcare budgets. Meanwhile, new development policies and high sustainability demands are driving innovations in device development to create patient-focused and sustainable drug delivery solutions.
